440 related articles for article (PubMed ID: 31564834)
1. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
[TBL] [Abstract][Full Text] [Related]
2. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
4. It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients.
Martina E; Damiani G; Grieco T; Foti C; Pigatto PDM; Offidani A
Dermatol Ther; 2021 Mar; 34(2):e14841. PubMed ID: 33527659
[TBL] [Abstract][Full Text] [Related]
5. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
[TBL] [Abstract][Full Text] [Related]
6. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
7. Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
Apalla Z; Sidiropoulos T; Kampouropoulou E; Papageorgiou M; Lallas A; Lazaridou E; Smaragdi M; Delli F
Eur J Dermatol; 2020 Dec; 30(6):716-722. PubMed ID: 33258453
[TBL] [Abstract][Full Text] [Related]
8. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
Salman A; Demir G; Bekiroglu N
Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics, Investigations and Treatment in Children with Chronic Urticaria: An Observational Study.
Buono EV; Giannì G; Scavone S; Caffarelli C
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792886
[No Abstract] [Full Text] [Related]
13. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
[TBL] [Abstract][Full Text] [Related]
14. [Omalizumab for the treatment of chronic urticaria: Real-life findings].
Hamelin A; Amsler E; Mathelier-Fusade P; Pecquet C; Bayrou O; Barbaud A; Soria A
Ann Dermatol Venereol; 2019 Jan; 146(1):9-18. PubMed ID: 30638684
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study.
Hide M; Igarashi A; Yagami A; Chinuki Y; Inomata N; Fukunaga A; Kaiser G; Wang J; Matsushima S; Greenberg S; Khalil S
Allergol Int; 2018 Apr; 67(2):243-252. PubMed ID: 29102514
[TBL] [Abstract][Full Text] [Related]
16. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
17. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
18. Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study.
Savic S; Leeman L; El-Shanawany T; Ellis R; Gach JE; Marinho S; Wahie S; Sargur R; Bewley AP; Nakonechna A; Randall R; Fragkas N; Somenzi O; Marsland A
Clin Exp Dermatol; 2020 Dec; 45(8):1003-1010. PubMed ID: 32246853
[TBL] [Abstract][Full Text] [Related]
19. Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
[TBL] [Abstract][Full Text] [Related]
20. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.
Bostan E; Zaid F; Karaduman A; Dogan S; Gulseren D; Yalici-Armagan B; Akdogan N; Ersoy-Evans S; Elcin G
J Cosmet Dermatol; 2021 Nov; 20(11):3369-3375. PubMed ID: 34599630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
